Research programme: cancer therapeutics - Fate Therapeutics/Juno Therapeutics

Drug Profile

Research programme: cancer therapeutics - Fate Therapeutics/Juno Therapeutics

Latest Information Update: 26 Aug 2015

Price : $50

At a glance

  • Originator Fate Therapeutics; Juno Therapeutics
  • Class CAR-T cell therapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 06 May 2015 Fate Therapeutics and Juno Therapeutics agree to co-develop chimeric antigen receptor (CAR T) and high-affinity T cell receptor (TCR) therapies in USA for Cancer
  • 06 May 2015 Early research in Cancer in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top